How do you give octreotide infusion?
How do you give octreotide infusion?
In emergency situations, octreotide may be administered undiluted by intermittent direct IV injection. Give IV slowly over 3 minutes. Dilute in 50 mL to 200 mL of 0.9% Sodium Chloride or 5% Dextrose injection; infuse IV over 15 to 30 minutes. Once diluted, the infusion solution is stable for 24 hours.
How do you titrate octreotide?
Titration: If frequent supplementary SubQ doses are needed (eg, ≥3 to 4 times/week), may increase the dose by 10 mg every 4 weeks, or maintain the same dose and reduce the dosing interval to every 3 weeks (Oberg 2004). Dosage range: 20 to 60 mg every 4 weeks.
Can subcutaneous octreotide be given IV?
Octreotide acetate injection may be administered subcutaneously or intravenously. Subcutaneous injection is the usual route of administration of octreotide acetate injection for control of symptoms. Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose.
What is octreotide GTT used for?
Octreotide is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive …
When can I stop octreotide infusion?
If no relevant reduction in GH levels and no improvement in clinical symptoms have been achieved within 3 months of starting treatment with Octreotide, therapy should be discontinued. Initially 0.05 mg once or twice daily by s.c. injection.
What are the side effects of octreotide?
Octreotide injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- pale, bulky, foul-smelling stools.
- constantly feeling the need to empty the bowels.
- stomach pain.
When should I stop octreotide drip?
For patients on a stable dose of Octreotide, assessment of GH and IGF-1 should be made every 6 months. If no relevant reduction in GH levels and no improvement in clinical symptoms have been achieved within 3 months of starting treatment with Octreotide, therapy should be discontinued.
Where do you inject octreotide subcutaneously?
There are 2 types of Octreotide: a short-acting medicine (sub-Q Octreotide) and a long-acting medicine (Sandostatin LAR). The short-acting medicine is given by subcutaneous injection (sub-Q shot) into the fat layer under the skin.
Is octreotide a chemo drug?
Octreotide – Chemotherapy Drugs – Chemocare.
How long does octreotide stay in your system?
Long acting octreotide is slowly absorbed by the body. This means that the drug stays in your body for longer. You usually have long acting octreotide as an injection into the muscle in your bottom once every 4 weeks.
Can octreotide cause weight loss?
Octreotide LAR given at 40 or 60 mg resulted in statistically significant weight loss. A post hoc analysis stratifying patients by race and CIRgp indicated that Caucasian patients with the greater degree of insulin hypersecretion appeared to derive the most benefit from treatment.
How long does octreotide drip last?
The recommended duration of octreotide therapy is based largely on expert opinion, however a 72-hour duration of treatment is likely to be unnecessary and may inappropriately increase hospital and medical costs….
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
How often can I take octreotide subcutaneously?
Usual Adult Dose for Acromegaly Initial dose: 50 mcg, IV or subcutaneously, 3 times a day Maintenance dose: Usually 100 mcg, 3 times a day Maximum dose: 500 mcg, 3 times a day
How often should you take octreotide for carcinoid tumors?
Usual Adult Dose for Carcinoid Tumor. Initial dose: 100 to 600 mcg per day, IV or subcutaneously, in 2 to 4 divided doses. Comments: -The median daily dose was 450 mcg; mean daily dose was 300 mcg.
When to switch to long acting octreotide depot?
Long-Acting depot formulation (Establish tolerability with short acting product for at least 2 weeks before using this formulation): Initial dose: 20 mg, IM (intragluteally), at 4 week intervals, for 2 months; continue with dose of regular octreotide for at least 2 weeks (at same dose patient was on before the switch)
Are there any uncontrolled trials for octreotide acetate?
Uncontrolled trials of both IV and subcutaneous octreotide have shown benefit in patients with ileostomy-associated diarrhea; however, in some cases the benefits have been offset by an increase in diarrhea due to fat malabsorption.